<DOC>
	<DOCNO>NCT00006032</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . Combining chemotherapy peripheral stem cell transplantation may allow doctor give high dos chemotherapy drug kill tumor cell . PURPOSE : Phase II trial study effectiveness combination chemotherapy follow autologous peripheral stem cell transplantation treat woman metastatic breast cancer .</brief_summary>
	<brief_title>Combination Chemotherapy Followed Peripheral Stem Cell Transplantation Treating Women With Metastatic Breast Cancer</brief_title>
	<detailed_description>OBJECTIVES : I . Evaluate efficacy toxicity high dose topotecan ifosfamide etoposide follow autologous peripheral blood stem cell rescue woman metastatic breast cancer . II . Evaluate response rate , progression free survival , engraftment , nonrelapse related mortality woman treat regimen . III . Evaluate pharmacokinetic profile high dose topotecan respect efficacy toxicity ifosfamide etoposide woman . OUTLINE : Peripheral blood stem cell ( PBSC ) harvest patient store . Patients receive ifosfamide IV 2 hour topotecan IV 30 minute day -8 -6 , etoposide IV daily 24 hour day -5 -3 . Autologous PBSC reinfused day 0 . Patients follow 1 , 3 , 6 , 12 month , every 6 month thereafter . PROJECTED ACCRUAL : A total 20-40 patient accrue study 2 year .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Etoposide</mesh_term>
	<mesh_term>Etoposide phosphate</mesh_term>
	<mesh_term>Isophosphamide mustard</mesh_term>
	<mesh_term>Ifosfamide</mesh_term>
	<mesh_term>Topotecan</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm metastatic breast cancer demonstrate least partial response salvage regimen Partial response define least 50 % reduction measurable evaluable disease least 4 week , disease progression , new lesion , bone lesion remain static least 8 week improvement pain symptoms No 3 organ involve metastatic disease No prior active CNS involvement Hormone receptor status : Not specify PATIENT CHARACTERISTICS : Age : 18 64 Sex : Female Menopausal status : Not specify Performance status : ECOG 01 Life expectancy : Not specify Hematopoietic : Not specify Hepatic : Bilirubin great 2.0 mg/dL SGOT SGPT great 2.5 time upper limit normal No history severe hepatic dysfunction Renal : Creatinine great 2.0 mg/dL OR Creatinine clearance least 60 mL/min Cardiovascular : No severe cardiac dysfunction Ejection fraction least 50 % MUGA No major heart disease Controlled hypertension allow Pulmonary : DLCO least 50 % normal OR No symptomatic obstructive restrictive disease Other : Not pregnant nursing Negative pregnancy test Fertile patient must use effective barrier contraception No uncontrolled insulin dependent diabetes mellitus No uncompensated major thyroid adrenal dysfunction No significant skin breakdown tumor disease No prior malignancy past 5 year except nonmelanoma skin cancer carcinoma situ cervix No active infection HIV negative PRIOR CONCURRENT THERAPY : Biologic therapy : Not specify Chemotherapy : See Disease Characteristics No 2 prior salvage regimens metastatic disease No prior topotecan Endocrine therapy : Not specify Radiotherapy : Not specify Surgery : Not specify Other : No concurrent nitroglycerin preparation angina No concurrent antiarrhythmic major ventricular arrhythmia</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>64 Years</maximum_age>
	<verification_date>December 2012</verification_date>
	<keyword>stage IV breast cancer</keyword>
	<keyword>recurrent breast cancer</keyword>
</DOC>